Compbio, Pharma, and Ramblings
Subscribe
Sign in
Home
Archive
About
Edition #16
CPS1, base editors, and ramblings...
May 30
•
Tommer
3
1
Edition #15
Otoferlin, hearing loss, and ramblings
Mar 11
•
Tommer
3
1
Edition #14
Sana, allogeneic cell therapy, and ramblings...
Jan 28
•
Tommer
1
Edition #13
Oura, wearables, and ramblings...
Jan 7
•
Tommer
2
Edition #12
ESM3, protein design, and ramblings...
Nov 21, 2024
•
Tommer
2
Latest
Top
Discussions
Edition #11
Muscarinic receptors, schizophrenia, and ramblings...
Oct 29, 2024
•
Tommer
2
Edition #10
Wastewater, phylogeny, and ramblings...
Sep 24, 2024
•
Tommer
3
1
Edition #9
Grail, cell-free DNA, and ramblings...
Aug 24, 2024
•
Tommer
2
Edition #8
Genetics, risk scores, and ramblings...
Jun 4, 2024
•
Tommer
2
Edition #7
Ginkgo, synthetic biology, and ramblings...
Mar 9, 2024
•
Tommer
3
Edition #6
CAR-T, TILs, and ramblings...
Feb 23, 2024
•
Tommer
6
Edition #5
Epigenetics, aging, and ramblings...
Feb 8, 2024
•
Tommer
6
1
See all
Compbio, Pharma, and Ramblings
A semi-regular note about computational biology and pharma. Not to say these are the only things going on in those worlds, but just some that are worth talking about.
Subscribe
Compbio, Pharma, and Ramblings
Subscribe
About
Archive
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts